THE LEADING AGGREGATED SUPPLIER OF

OEM & AFTERMARKET SPARE PARTS

null
FOCKE, AIGER, DECOUFLE, SASIB, MARDEN EDWARDS
MARKETPLACE

BENEFITS

null
Smart Part Search

Largest Online Inventory -Global inventory network of 10,000+ ready and hard to find parts

null
Quality Verified Suppliers

Smart Part Search - Consolidated sourcing options and the easy messaging tool enables collection of transparent information and quick selection

null
Reduce Time

Reduce time - search parts, exchange technical specifications and the PO/Invoice over one platform

null
Largest Online Inventory

Quality Verified Network - Largest Online Inventory IZIPART Global supply network ensures quality & reliable sourcing

TESTIMONIALS

We have purchased our spare parts via IZIPART multiple times. Sourcing Original spares has been easy and transparent. Highly recommended.

 

Copper Leaf Tobacco Company, Zambia

By: Purchase Manager 

 

Via IZIPART we were able to access multiple supply solutions for an urgent spare part quickly and easily. The communication and purchase process was simple and transparent. We will definitely use IZIPART next time!

 

Al Fakher, UAE

By:Head of Maintenance & Procurement

 

LATEST INDUSTRY NEWS

25th’ March’ 2020

Canada

Advances  made on COVID-19 Vaccine

 

READ MORE

BLOG

Latest news from machine parts community

  • Advances made on COVID-19 vaccine

     

    24 Mar 2020. Medicago, a Canadian biopharmaceutical company partially owned by Philip Morris International, has made significant progress on a COVID-19 vaccine, according to a PMI press release.

    Medicago is using a virus-like particle (VLP) which is grown in Nicotiana Benthamiana, a close relative of the tobacco plant, to develop a vaccine against COVID-19. The company, which is partially funded by PMI, has announced it is ready to begin preclinical testing for safety and efficacy and estimates that human trials will be able to begin later this summer.

     

    According to the press release, Medicago focuses on plant-based technology, which uses particles similar to viruses, rather than focusing on animal products or live viruses. The advantage of this is that VLPs mimic viruses. The body’s immune system then recognises them and this triggers an immune response, but because there is no core genetic material in a VLP, they are not infectious and will not replicate. This enables the company to mass-produce therapies which can counter act a pandemic, like COVID-19, within a very short amount of time.

     

    In addition to a COVID-19 virus, Medicago has also developed a seasonal flu vaccine, which is currently under review by Health Canada, and is working on developing antibodies against SARS-CoV-2. This is being developed in conjunction with Laval University’s Infectious Disease Centre and these antibodies could potentially be used to help treat those infected with coronavirus. PMI acquired a stake in Medicago in 2013 and currently owns around one third of the company’s shares.

     

    (source: http://www.tobaccojournal.com/Advances_made_on_COVID-19_vaccine.55745.0.html)